Plazomicin

Drug Profile

Plazomicin

Alternative Names: ACHN-490; Plazomicin sulfate

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Achaogen
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bacteraemia; Nosocomial pneumonia; Pyelonephritis; Urinary tract infections
  • Preclinical Gram-negative infections; Respiratory tract infections; Tularaemia; Yersinia infections

Most Recent Events

  • 13 Dec 2016 Efficacy and adverse events data from the phase III CARE trial in Bacteraemia released by Achaogen
  • 13 Dec 2016 Efficacy and adverse events data from the phase III EPIC trial in Urinary tract infections released by Achaogen
  • 01 Sep 2016 Achaogen completes the phase III EPIC trial for Urinary tract infections and Pyelonephritis in USA, Bulgaria, Estonia, Georgia, Germany, Hungary, Latvia, Poland, Romania, Russia, Serbia, Ukrain, and Spain (NCT02486627, EudraCT2015-001588-37)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top